Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 15/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112084 | 0.72 | SMN1; SMN2 (0.45) | CA2POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL5521516 | 0.72 | SMN1; SMN2 (0.45) | CA2POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL13811563 | 0.72 | SMN1; SMN2 (0.45) | CA2POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL2112086 | 0.72 | SMN1; SMN2 (0.45) | CA2POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL2112085 | 0.72 | SMN1; SMN2 (0.45) | CA2POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL3075586 | 0.67 | ALDH1A1 (0.51) | PKMADORA2BALDH1A1POLBHSD17B10 | |
| SCHEMBL11428571 | 0.67 | PKM (0.55) | PKMADORA2BMCL1ALDH1A1 | |
| SCHEMBL8426250 | 0.67 | ALDH1A1 (0.51) | PKMADORA2BALDH1A1POLBHSD17B10 | |
| SCHEMBL13580146 | 0.67 | ALDH1A1 (0.51) | PKMADORA2BALDH1A1POLBHSD17B10 | |
| SCHEMBL8430355 | 0.66 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083497-A1 | Taxoids, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA, S.A. | 2003-05-01 | — | — | US | disclosed |
| US-6384071-B2 | ANTITUMOR AGENTS | AVENTIS PHARMA, S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| US-20010021783-A1 | New taxoids, their preparation and pharmaceutical compositions containing them | Rhône-Poulenc Rorer S.A. | 2001-09-13 | — | — | US | disclosed |
| US-6194582-B1 | MULTI-DRUG RESISTANCE | RHONE-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| US-5939561-A | Process for the preparation of β-phenylisoserine and β-lactam and their analogues | RHONE-POULENCE RORER S.A. (FR) | 1999-08-17 | — | — | US | disclosed |
| US-5814658-A | Taxoids, their preparation and pharmaceutical compositions containing them | RHONE-POULENC RORER S.A. (FR) | 1998-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083497-A1 | Taxoids, their preparation and pharmaceutical compositions containing them | TBXA2R, CBR1, CBR3 | PKM 2695/4885ADORA2B 1044/4885CA2 3445/4885 |
| US-20010021783-A1 | New taxoids, their preparation and pharmaceutical compositions containing them | CBR1, TBXA2R, CBR3 | PKM 2502/4885ADORA2B 929/4885CA2 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.